|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Towards 6G wireless communication networks:vision,enabling technologies,and new paradigm shifts显示文摘The fifth generation(5G)wireless communication networks are being deployed worldwide from 2020 and more capabilities are in the process of being standardized,such as mass connectivity,ultra-reliability,and guaranteed low latency.However,5G will not meet all requirements of the future in 2030 and beyond,and sixth generation(6G)wireless communication networks are expected to provide global coverage,enhanced spectral/energy/cost efficiency,better intelligence level and security,etc.To meet these requirements,6G networks will rely on new enabling technologies,i.e.,air interface and transmission technologies and novel network architecture,such as waveform design,multiple access,channel coding schemes,multi-antenna technologies,network slicing,cell-free architecture,and cloud/fog/edge computing.Our vision on 6G is that it will have four new paradigm shifts.First,to satisfy the requirement of global coverage,6G will not be limited to terrestrial communication networks,which will need to be complemented with non-terrestrial networks such as satellite and unmanned aerial vehicle(UAV)communication networks,thus achieving a space-airground-sea integrated communication network.Second,all spectra will be fully explored to further increase data rates and connection density,including the sub-6GHz,millimeter wave(mmWave),terahertz(THz),and optical frequency bands.Third,facing the big datasets generated by the use of extremely heterogeneous networks,diverse communication scenarios,large numbers of antennas,wide bandwidths,and new service requirements,6G networks will enable a new range of smart applications with the aid of artificial intelligence(AI)and big data technologies.Fourth,network security will have to be strengthened when developing 6G networks.This article provides a comprehensive survey of recent advances and future trends in these four aspects.Clearly,6G with additional technical requirements beyond those of 5G will enable faster and further communications to the extent that the boundary between physical and cyber worlds disappears. | Xiaohu YOU Cheng-Xiang WANG Jie HUANG Xiqi GAO Zaichen ZHANG Mao WANG Yongming HUANG Chuan ZHANG Yanxiang JIANG Jiaheng WANG Min ZHU Bin SHENG Dongming WANG Zhiwen PAN Pengcheng ZHU Yang YANG Zening LIU Ping ZHANG Xiaofeng TAO Shaoqian LI Zhi CHEN Xinying MA Chih-Lin I Shuangfeng HAN Ke LI Chengkang PAN Zhimin ZHENG Lajos HANZO Xuemin(Sherman)SHEN Yingjie Jay GUO Zhiguo DING Harald HAAS Wen TONG Peiying ZHU Ganghua YANG Jun WANG Erik GLARSSON Hien Quoc NGO Wei HONG Haiming WANG Debin HOU Jixin CHEN Zhe CHEN Zhangcheng HAO Geoffrey Ye LI Rahim TAFAZOLLI Yue GAO HVincent POOR Gerhard P.FETTWEIS Ying-Chang LIANG | 2021 | Science China(Information Sciences)2021，64，1： | 122 |
| 2 | Semi-Fredholm Spectrum and Weyl's Theorem for Operator Matrices显示文摘当鈭? B (H)和 B 鈭? B (K)被给时,我们由 M C 表示在这份报纸对形式的 Hilbert 空间 H 鈯? K 起作用的一个操作员,首先,我们为是上面的 semi-Fredholm (更低的半 鈥揊r edholm ,或 Fredholm )的 M C 给必要、足够的条件为一些 C 鈭? B 的操作员( K , H )。另外,让(A)={ 位鈭吗?? :A?位 I 不是一个上面的 semi-Fredholm 操作员 } 鈭 ? B 的上面的半鈥揊r edholm 光谱是(H) 并且让(A)={ 位鈭吗?? :A?位 I 不是一个更低的半鈥揊r edholm 操作员 } 是 A 的更低的半鈥揊r edholm 光谱。我们证明经过从被移开某些开的子集完成从前者,也就是说。 | Xiao Hong CAO Mao Zheng GUO Bin MENG | 2006 | Acta Mathematica Sinica,English Series2006，22，1： | 34 |
| 3 | Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study显示文摘 | Ying Zheng Guang-Yan Cai Li-Qun He Hong-Li Lin Xiao-Hong Cheng Nian-Song Wang Gui-Hua Jian Xu-Sheng Liu Yu-Ning Liu Zhao-Hui Ni Jing-Ai Fang Han-Lu Ding Wang Guo Ya-Ni He Li-Hua Wang Ya-Ping Wang Hong-Tao Yang Zhi-Ming Ye Ren-Huan YU Li-Juan Zhao Wen-Hua Zhou Wen-Ge Li Hui-Juan Mao Yong-Li Zhan Zhao Hu Chen Yao Ri-Bao Wei Xiang-Mei Chen | 2017 | Chinese Medical Journal2017，，20： | 21 |
| 4 | Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database显示文摘Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China. | Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang | 2015 | Asian Journal of Urology2015，2，2： | 21 |
| 5 | Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China显示文摘Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.Methods A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.Results Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two weeks.Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes. | MA Yan ZHU Dong Shan CHEN Ren Bo SHI Nan Nan LIU Si Hong FAN Yi Pin WU Gui Hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN Li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU Yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI Liang JIN Hai Hao LEI Xiao LI Chun Yan LI Min Qing LI Qun Tang LI Xian Yong LIU Hong De LIU Jin Ping LIU Zhang MA Yu Ting MAO Ya MO Liu Fen NA Hui WANG Jing Wei SONG Fang Li SUN Sheng WANG Dong Ting WANG Ming Xuan WANG Xiao Yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping XIAO Yan Hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun YUAN Sheng Li ZHANG Gong Qi ZHANG Jin Bo ZHANG Lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 无 | 2020 | Biomedical and Environmental Sciences2020，33，12： | 8 |
| 6 | Effects of Niaoduqing Particles(尿毒清颗粒)on Delaying Progression of Renal Dysfunction:A Post-trial,Open-Label,Follow-up Study显示文摘Objective: To follow up the participants of the randomized clinical trial 'Efficacy and Safety of Niaoduqing Particles(尿毒清颗粒) for Delaying Moderate-to-Severe Renal Dysfunction', and assess the long-term effects of Niaoduqing Particles on delaying the progression of renal dysfunction. Methods: Participants, who had previously been randomly assigned to receive Niaoduqing Particles or placebo for 24 weeks(146 cases in each group), were invited to follow-up and all were administered Niaoduqing Particles 5 g thrice daily and 10 g before bedtime for 24 weeks. The primary endpoints were changes in baseline serum creatinine(Scr) and estimated glomerular filtration rate(e GFR) after completion of the open-label treatment period. Results: After the double-blind period, the median(interquartile range) changes in Scr were 1.1(–13.0–24.1) and 11.7(–2.6–42.9) μmol/L for the Niaoduqing Particle and placebo groups, respectively(P=0.008), and the median changes in e GFRs were –0.2(–4.3–2.7) and –2.21(–5.7–0.8) mL·min^(-1)·1.73 m^(-2), respectively(P=0.016). There were significant differences in the double-blind period changes in renal function between groups. After the open-label period, the median changes in Scr were 9.0(–10.0–41.9) and 17.5(–6.0–50.0) μmol/L for the Niaoduqing Particle and placebo groups according to baseline grouping, respectively(P=0.214), and the median changes in eGFRs were –2.3(–6.4–1.9) and –3.7(–7.5–1.1) mL·min^(-1)·1.73 m^(-2), respectively(P=0.134). There were no statistical differences in the open-label period changes in renal function between groups. The eGFR reduction of participants who accepted Niaoduqing Particle treatment for 48 weeks was projected to 2.5 m L·min^(-1)·1.73 m(-2) per year. Conclusions: Niaoduqing Particles appear to have long-term efficacy for patients with moderate-to-severe renal dysfunction. Although there was no statistical difference, the early use of Niaoduqing Paticles seems to ameliorate the worsening of renal function. | ZHENG Ying WANG Nian-song LIU Yu-ning HE Li-qun JIAN Gui-hua LIU Xu-sheng NI Zhao-hui CHENG Xiao-hong LIN Hong-li ZHOU Wen-hua WANG Ya-ping FANG Jing-ai HE Ya-ni YANG Hong-tao ZHAO Li-juan DING Han-lu WANG Li-hua YU Ren-huan LI Wen-ge YE Zhi-ming GUO Wang ZHAN Yong-li MAO Hui-juan HU Zhao YAO Chen CAI Guang-yan CHEN Xiang-mei | 2019 | Chinese Journal of Integrative Medicine2019，25，3： | 7 |
| 7 | The Lyman-alpha Solar Telescope(LST) for the ASO-S mission——Ⅱ. design of LST显示文摘As one of the three payloads for the Advanced Space-based Solar Observatory(ASO-S)mission,the Lyman-alpha(Lyα)Solar Telescope(LST)is composed of three instruments:a Solar Corona Imager(SCI),a LyαSolar Disk Imager(SDI)and a full-disk White-light Solar Telescope(WST).When working in-orbit,LST will simultaneously perform high-resolution imaging observations of all regions from the solar disk to the inner corona up to 2.5 R⊙(R⊙stands for the mean solar radius)with a spatial resolution of 4.8′′and 1.2′′for coronal and disk observations,respectively,and a temporal resolution of 30–120 s and 1–120 s for coronal and disk observations,respectively.The maximum exposure time can be up to20 s due to precise pointing and image stabilization function.Among the three telescopes of LST,SCI is a dual-waveband coronagraph simultaneously and independently observing the inner corona in the HI Lyα(121.6±10 nm)line and white light(WL)(700±40 nm)wavebands by using a narrowband Lyαbeam splitter and has a field of view(FOV)from 1.1 to 2.5 R⊙.The stray-light suppression level can attain<10^-6 B⊙(B⊙is the mean brightness of the solar disk)at 1.1 R⊙and≤5×10^-8 B⊙at 2.5 R⊙.SDI and WST are solar disk imagers working in the Lyαline and 360.0 nm wavebands,respectively,which adopt an off-axis two-mirror reflective structure with an FOV up to 1.2 R⊙,covering the inner coronal edge area and relating to coronal imaging.We present the up-to-date design for the LST payload. | Bo Chen Hui Li Ke-Fei Song Quan-Feng Guo Pei-Jie Zhang Ling-Ping He Shuang Dai Xiao-Dong Wang Hai-Feng Wang Chun-Long Liu Hong-Ji Zhang Guang Zhang Yunqi Wang Shi-Jie Liu Hong-Xin Zhang Lei Liu Shi-Lei Mao Yang Liu Jia-Hao Peng Peng Wang Liang Sun Yang Liu Zhen-Wei Han Yan-Long Wang Kun Wu Guang-Xing Ding Peng Zhou Xin Zheng Ming-Yi Xia Qing-Wen Wu Jin-Jiang Xie Ya Chen Shu-Mei Song Hong Wang Bo Zhu Chang-Bo Chu Wen-Gang Yang Li Feng Yu Huang Wei-Qun Gan Ying Li Jing-Wei Li Lei Lu Jian-Chao Xue Bei-Li Ying Ming-Zhe Sun Cheng Zhu Wei-Min Bao Lei Deng Zeng-Shan Yin | 2019 | Research in Astronomy and Astrophysics2019，19，11： | 6 |
| 8 | Dark matter direct search sensitivity of the PandaX-4T experiment显示文摘The Panda X-4T experiment, a 4-ton scale dark matter direct detection experiment, is being planned at the China Jinping Underground Laboratory. In this paper we present a simulation study of the expected background in this experiment. In a 2.8-ton fiducial mass and the signal region between 1-10 keV electron equivalent energy, the total electron recoil background is found to be 4.9 × 10^(-5) kg^(-1) d^(-1) keV^(-1). The nuclear recoil background in the same region is 2.8 × 10^(-7) kg^(-1) d^(-1) keV^(-1). With an exposure of 5.6 ton-years, the sensitivity of Panda X-4 T could reach a minimum spin-independent dark matter-nucleon cross section of 6 × 10^(-48) cm^2 at a dark matter mass of 40 Ge V/c^2. | HongGuang Zhang Abdusalam Abdukerim Wei Chen Xun Chen YunHua Chen XiangYi Cui BinBin Dong DeQing Fang ChangBo Fu Karl Giboni Franco Giuliani LinHui Gu XuYuan Guo ZhiFan Guo Ke Han ChangDa He ShengMing He Di Huang XingTao Huang Zhou Huang Peng Ji XiangDong Ji YongLin Ju ShaoLi Li Yao Li Heng Lin HuaXuan Liu JiangLai Liu YuGang Ma YaJun Mao KaiXiang Ni JinHua Ning XiangXiang Ren Fang Shi AnDi Tan AnQing Wang Cheng Wang HongWei Wang Meng Wang QiuHong Wang SiGuang Wang XiuLi Wang XuMing Wang Zhou Wang MengMeng Wu ShiYong Wu JingKai Xia MengJiao Xiao PengWei Xie BinBin Yan JiJun Yang Yong Yang ChunXu Yu JuMin Yuan JianFeng Yue Dan Zhang Tao Zhang Li Zhao QiBin Zheng JiFang Zhou Ning Zhou XiaoPeng Zhou | 2019 | Science China(Physics,Mechanics & Astronomy)2019，62，3： | 6 |
| 9 | Selection of reliable reference genes for gene expression study in nasopharyngeal carcinoma显示文摘 | Yi GUO Jia-xin CHEN Shu YANG Xu-ping FU Zheng ZHANG Ke-he CHEN Yan HUANG Yao LI Yi XIE Yu-min MAO | 2010 | Acta Pharmacologica Sinica2010，31，11： | 5 |
| 10 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 11 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)显示文摘Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC. | Hui-Chuan Sun Jian Zhou Zheng Wang Xiufeng Liu Qing Xie Weidong Jia Ming Zhao Xinyu Bi Gong Li Xueli Bai Yuan Ji Li Xu Xiao-Dong Zhu Dousheng Bai Yajin Chen Yongjun Chen Chaoliu Dai Rongping Guo Wenzhi Guo Chunyi Hao Tao Huang Zhiyong Huang Deyu Li Gang Li Tao Li Xiangcheng Li Guangming Li Xiao Liang Jingfeng Liu Fubao Liu Shichun Lu Zheng Lu Weifu Lv Yilei Mao Guoliang Shao Yinghong Shi Tianqiang Song Guang Tan Yunqiang Tang Kaishan Tao Chidan Wan Guangyi Wang Lu Wang Shunxiang Wang Tianfu Wen Baocai Xing Bangde Xiang Sheng Yan Dinghua Yang Guowen Yin Tao Yin Zhenyu Yin Zhengping Yu Bixiang Zhang Jialin Zhang Shuijun Zhang Ti Zhang Yamin Zhang Yubao Zhang Aibin Zhang Haitao Zhao Ledu Zhou Wu Zhang Zhenyu Zhu Shukui Qin Feng Shen Xiujun Cai Gaojun Teng Jianqiang Cai Minshan Chen Qiang Li Lianxin Liu Weilin Wang Tingbo Liang Jiahong Dong Xiaoping Chen Xuehao Wang Shusen Zheng Jia Fan 无 | 2022 | Hepatobiliary Surgery and Nutrition2022，11，2： | 4 |
| 12 | Synthesis of layered double hydroxides/graphene oxide nanocomposite as a novel high-temperature CO_2 adsorbent显示文摘In this contribution, a novel high-temperature CO2 adsorbent consisting of Mg-Al layered double hydroxide(LDH) and graphene oxide(GO)nanosheets was prepared and evaluated. The nanocomposite-type adsorbent was synthesized based on the electrostatically driven self-assembly between positively charged Mg-Al LDH single sheet and negatively charged GO monolayer. The characteristics of this novel adsorbent were investigated using XRD, FE-SEM, HRTEM, FT-IR, BET and TGA. The results showed that both the CO2 adsorption capacity and the multicycle stability of LDH were increased with the addition of GO owing to the enhanced particle dispersion and stabilization. In particular, the absolute CO2 capture capacity of LDH was increased by more than twice by adding 6.54 wt% GO as support. GO appeared to be especially effective for supporting LDH sheets. Moreover, the CO2 capture capacity of the adsorbent could be further increased by doping with 15 wt%K2CO3. This work demonstrated a new approach for the preparation of LDH-based hybrid-type adsorbents for CO2 capture. | Junya Wang Xueyi Mei Liang Huang Qianwen Zheng Yaqian Qiao Ketao Zang Shengcheng Mao Ruoyan Yang Zhang Zhang Yanshan Gao Zhanhu Guo Zhanggen Huang Qiang Wang | 2015 | Journal of Energy Chemistry2015，24，2： | 4 |
| 13 | Stable Lithium-Carbon Composite Enabled by Dual-Salt Additives显示文摘Lithium metal is regarded as the ultimate negative electrode material for secondary batteries due to its high energy density.However,it suffers from poor cycling stability because of its high reactivity with liquid electrolytes.Therefore,continuous efforts have been put into improving the cycling Coulombic efficiency(CE)to extend the lifespan of the lithium metal negative electrode.Herein,we report that using dual-salt additives of LiPF_(6) and LiNO_(3) in an ether solvent-based electrolyte can significantly improve the cycling stability and rate capability of a Li-carbon(Li-CNT)composite.As a result,an average cycling CE as high as 99.30% was obtained for the Li-CNT at a current density of 2.5 mA cm^(-2) and an negative electrode to positive electrode capacity(N/P)ratio of 2.The cycling stability and rate capability enhancement of the Li-CNT negative electrode could be attributed to the formation of a better solid electrolyte interphase layer that contains both inorganic components and organic polyether.The former component mainly originates from the decomposition of the LiNO_(3) additive,while the latter comes from the LiPF_(6)-induced ring-opening polymerization of the ether solvent.This novel surface chemistry significantly improves the CE of Li negative electrode,revealing its importance for the practical application of lithium metal batteries. | Lei Zheng Feng Guo Tuo Kang Yingzhu Fan Wei Gu Yayun Mao Ya Liu Rong Huang Zhiyun Li Yanbin Shen Wei Lu Liwei Chen | 2021 | Nano-Micro Letters2021，13，7： | 3 |
| 14 | Study of the Retinal Imaging and Output in Premature Baby under a Computer-assisted Binocular Indirect Ophthalmoscope显示文摘Purpose:To explore a clear retinal imaging and output and enhance the development of retinopathy of prematurity (ROP) screening,which is safe and effective for ROP screening in premature infants. Methods:A computer-assisted binocular indirect ophthalmoscope imaging and output system was equipped with camera and image processing hardware and connected to computers. The process of fundus examination was videotaped (photograph) and output. Simulated eyes were utilized to debug video head and acquire stable and clear fundus images by binocular indirect ophthalmoscope for premature infants. Results:Fundus imaging output technique was sucessfully established. The common reasons of unclear imaging and corresponding solutions were summarized. This technique can capture and output stable and clear fundus images of premature infants. Conclusion: Assisted by hardware and software processing, a compute assisted binocular indirect ophthalmoscope imaging and output system was established,which can be used for screening, research, treatment and follow-up of ROP in premature babies to resolve the difficulty in obtaining clear fundus photograph. | Daoman Xiang Feng Chen Jianxun Wang Zheng Guo Lihong Chen Yani Mao | 2012 | Eye Science2012，27，4： | 3 |
| 15 | Deformation mechanism of fine grained Mg-7Gd-5Y-l.2Nd-0.5Zr alloy under high temperature and high strain rates显示文摘Fine grained Mg-7Gd-5Y-1.2Nd-0.5Zr alloy was investigated by dynamic compression tests using a Split Hopkinson Pressure Bar under the strain rates in the range 1000-2000 s^(-1) and the temperature range 293-573 K along the normal direction.The microstructure was measured by optical microscopy,electron back-scattering diffraction,transmission electron microscopy and X-ray diffractometry.The results showed that Mg-7Gd-5Y-1.2Nd-0.5Zr alloy had the positive strain rate strengthening effect and thermal softening effect at high temperature.The solid solution of Gd and Y atoms in Mg-7Gd-5Y-1.2Nd-0.5Zr alloy reduced the asymmetry of α-Mg crystals and changed the critical shear stress of various deformation mechanisms.The main deformation mechanisms were prismatic slip and pyramidal(a)slip,{102}tension twinning,and dynamic recrystallization caused by local deformation such as particle-stimulated nucleation.c 2020 Published by Elsevier B.V.on behalf of Chongqing University. | Wanru Tang Zheng Liu Shimeng Liu Le Zhou Pingli Mao Hui Guo Xiaofang Sheng | 2020 | Journal of Magnesium and Alloys2020，8，4： | 2 |
| 16 | Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial显示文摘 | Lei Chen Chao-Su Hu Xiao-Zhong Chen Guo-Qing Hu Zhi-Bin Cheng Yan Sun Wei-Xiong Li Yuan-Yuan Chen Fang-Yun Xie Shao-Bo Liang Yong Chen Ting-Ting Xu Bin Li Guo-Xian Long Si-Yang Wang Bao-Min Zheng Ying Guo Ying Sun Yan-Ping Mao Ling-Long Tang Yu-Ming Chen | 2012 | Lancet Oncology2012，，2： | 2 |
| 17 | Cartilage oligomeric matrix protein is an endogenous β-arrestin-2-selective allosteric modulator of AT1 receptor counteracting vascular injury显示文摘Compelling evidence has revealed that biased activation of G protein-coupled receptor(GPCR)signaling,including angiotensin II(AngII)receptor type 1(AT1)signaling,plays pivotal roles in vascular homeostasis and injury,but whether a clinically relevant endogenous biased antagonism of AT1 signaling exists under physiological and pathophysiological conditions has not been clearly elucidated.Here,we show that an extracellular matrix protein,cartilage oligomeric matrix protein(COMP),acts as an endogenous allosteric biased modulator of the AT1 receptor and its deficiency is clinically associated with abdominal aortic aneurysm(AAA)development.COMP directly interacts with the extracellular N-terminus of the AT1 via its EGF domain and inhibits AT1-β-arrestin-2 signaling,but not Gq or Gi signaling,in a selective manner through allosteric regulation of AT1 intracellular conformational states.COMP deficiency results in activation of AT1a-β-arrestin-2 signaling and subsequent exclusive AAA formation in response to AngII infusion.AAAs in COMP–/–or ApoE–/–mice are rescued by AT1a orβ-arrestin-2 deficiency,or the application of a peptidomimetic mimicking the AT1-binding motif of COMP.Explorations of the endogenous biased antagonism of AT1 receptor or other GPCRs may reveal novel therapeutic strategies for cardiovascular diseases. | Yi Fu Yaqian Huang Zhao Yang Yufei Chen Jingang Zheng Chenfeng Mao Zhiqing Li Zhixin Liu Bing Yu Tuoyi Li Meili Wang Chanjuan Xu Yiwei Zhou Guizhen Zhao Yiting Jia Wei Guo Xin Jia Tao Zhang Li Li Ziyi Liu Shengchao Guo Mingliang Ma Heng Zhang Bo Liu Junbao Du Wengong Wang Chaoshu Tang Pei Gao Qingbo Xu Xian Wang Jianfeng Liu Jinpeng Sun Wei Kong | 2021 | Cell Research2021，31，7： | 2 |
| 18 | The Characterization of a Class of Quantum Markov Semigroups and the Associated Operator-Valued Dirichlet Forms Based on Hilbert W*-Module显示文摘In this paper, we introduce the concept of operator-valued quadratic form based on Hilbert W*-module l2 A, and give a one to one correspondence between the set of positive self-adjoint regular module operators on l2A and the set of regular quadratic forms, where A is a finite and σ-finite von Neumann algebra. Furthermore, we obtain that a strict continuous symmetric regular module operator semigroup {Tt }t∈R + L(l2A) is Markovian if and only if the associated A-valued quadratic form is a Dirichlet form, where L(l2A) is the von Neumann algebra of all adjointable module maps on l2A. | Lun Chuan ZHANG Mao Zheng GUO | 2013 | Acta Mathematica Sinica,English Series2013，29，5： | 1 |
| 19 | Fatigue behavior of magnesium alloy and application in auto steering wheel frame显示文摘 | Ping-li MAO Zheng LIU Chang-yi WANG Quan-ying GUO Jin SUN Feng WANG Li LIN | 2008 | Transactions of Nonferrous Metals Society of China2008，，： | 1 |
| 20 | The draft genome of watermelon (Citrullus lanatus ) and reseqnencing of 20 diverse accessions显示文摘 | Guo S G Zhang J G Sun H H Salse J Lucas W J Zhang H Y Zheng Y Mao L Y Ren Y WangZ W Min J M Guo X S Murat F Ham B K Zhang Z L Gao S Huang M Xu Y M Zhong S L Bombarely A Mueller L Zhao H He H Q Zhang Y Zhang Z H Huang S W Tan T Pang E Lin K Hu Q Kuang H H Ni P X Wang B Liu J G Kou Q H Hou W J Zou X H Jiang J Gong G Y Klee K Schoof H Huang Y Hu X S Dong S S Liang D Q Wang J Wu K Xia Y Zhao X Zheng Z Q Xing M Liang X M Huang B Q Lv T Wang J Y Yin Y Yi H P Li R Q Wu M Z Levi A Zhang X P Giovannoni J Wang J Li YF Fei Z J Xu Y | 2013 | Nature genetics2013，45，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员